AVALO THERAPEUTICS, INC. Lessee, Operating Lease, Liability, to be Paid, after Year Five
AVALO THERAPEUTICS, INC. (AVTX) had Lessee, Operating Lease, Liability, to be Paid, after Year Five of $0 as of 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive · last filed 2025-08-07
- 2025-06-30: Lessee, Operating Lease, Liability, to be Paid, after Year Five $0.00.
- 2025-03-31: Lessee, Operating Lease, Liability, to be Paid, after Year Five $0.00.
- 2024-09-30: Lessee, Operating Lease, Liability, to be Paid, after Year Five $17.00K.
- 2024-06-30: Lessee, Operating Lease, Liability, to be Paid, after Year Five $17.00K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, after Year Five |
|---|---|
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-12 |
| 2024-09-30 | $17.00K 10-Q · filed 2024-11-07 |
| 2024-06-30 | $17.00K 10-Q · filed 2024-08-12 |
| 2024-03-31 | $17.00K 10-Q/A · filed 2024-07-11 |
| 2023-12-31 | $224.00K 10-K · filed 2024-03-29 |
| 2023-09-30 | $224.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $224.00K 10-Q · filed 2023-08-03 |
| 2023-03-31 | $224.00K 10-Q · filed 2023-05-04 |
| 2022-12-31 | $426.00K 10-K · filed 2023-03-29 |
| 2022-09-30 | $426.00K 10-Q · filed 2022-11-07 |
| 2022-06-30 | $426.00K 10-Q · filed 2022-08-04 |
| 2022-03-31 | $426.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $683.00K 10-K · filed 2022-03-02 |
| 2021-09-30 | $621.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $621.00K 10-Q · filed 2021-08-02 |
| 2021-03-31 | $621.00K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $813.64K 10-K · filed 2021-03-08 |
| 2020-09-30 | $813.64K 10-Q · filed 2020-11-09 |
| 2020-06-30 | $813.64K 10-Q · filed 2020-08-06 |
| 2019-12-31 | $1.00M 10-K · filed 2020-03-11 |
| 2019-09-30 | $1.18M 10-Q · filed 2019-11-14 |
| 2019-03-31 | $1.18M 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |